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Background: Our previous randomized double-blind study showed that drinking hydrogen (H2) water for 48 weeks
significantly improved the total Unified Parkinson’s Disease Rating Scale (UPDRS) score of Parkinson’s disease (PD)
patients treated with levodopa. We aim to confirm this result using a randomized double-blind placebo-controlled
multi-center trial.
Methods: Changes in the total UPDRS scores from baseline to the 8th, 24th, 48th, and 72nd weeks, and after the
8th week, will be evaluated. The primary endpoint of the efficacy of this treatment in PD is the change in the total
UPDRS score from baseline to the 72nd week. The changes in UPDRS part II, UPDRS part III, each UPDRS score, PD
Questionnaire-39 (PDQ-39), and the modified Hoehn and Yahr stage at these same time-points, as well as the
duration until the protocol is finished because additional levodopa is required or until the disease progresses, will
also be analyzed. Adverse events and screening laboratory studies will also be examined. Participants in the
hydrogen water group will drink 1000 mL/day of H2 water, and those in the placebo water group will drink normal
water. One-hundred-and-seventy-eight participants with PD (89 women, 89 men; mean age: 64.2 [SD 9.2] years,
total UPDRS: 23.7 [11.8], with levodopa medication: 154 participants, without levodopa medication: 24 participants;
daily levodopa dose: 344.1 [202.8] mg, total levodopa equivalent dose: 592.0 [317.6] mg) were enrolled in 14
hospitals and were randomized.
Discussion: This study will confirm whether H2 water can improve PD symptoms.
Trial registration: UMIN000010014 (February, 13, 2013)
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In patients with Parkinson’s disease (PD), the pharmaco-
logic replacement of dopamine and other antiparkinsonian
drugs has been used for symptomatic therapy. However,
none of these drugs stop or lessen the dopaminergic neur-
onal degeneration or the progression of the disease. Find-
ings of increased iron and lipid peroxidation and decreased
levels of reduced glutathione in the substantia nigra
strongly suggest that enhanced oxidative stress is involved
in the pathogenesis of PD [1, 2]. Thus, antioxidant therapies
might slow the progression of PD. Molecular hydrogen
(H2) has recently been highlighted as a therapeutic and pre-
ventive antioxidant. Since the first publication [3], more
than 150 papers have confirmed the efficacy of H2 in vari-
ous animal models [4]. H2-water reduced dopaminergic
neuronal cell loss in a 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP) mouse model [5] as well as 6-
hydroxydopamine did [6]. Our previous randomized
double-blind study has shown that drinking 1,000 mL of
H2-water for 48 weeks significantly improved (p < 0.05) the
total Unified Parkinson’s Disease Rating Scale (UPDRS)
scores of patients with PD who were being treated with
levodopa [7]. In the present study, we aimed to confirm
these results by conducting a longer and more large-scale
trial that also included patients who were not being treated
with levodopa. Here, we present the design and the baseline
characteristics of participants already enrolled in this study.Methods
A placebo-controlled, randomized, double-blind, parallel-
group (1:1) clinical multi-center trial was organized by the
Department of Neurology of Juntendo University School
of Medicine in accordance with Consolidated Standards of
Reporting Trials (CONSORT) guideline. Fourteen hospi-
tals are involved as trial centers. This trial was advertised
in posters and on homepages of our clinic, and partici-
pants had to declare their intentions to participate volun-
tarily. The inclusion criteria required that the participants
have a diagnosis of PD according to the United Kingdom
Brain Bank criteria [8]. All the participants should have a
modified Hoehn and Yahr staging (H & Y stage) in the on-
phase between 1 and 4. For 8 weeks prior to establishing
the baseline, the participants’ antiparkinsonian drugs were
not changed. None of the participants have dementia
(MMSE < 25) or dysphagia for water. Outpatients are pre-
ferred over admitted patients. The participants are to be
older than 20 years. The exclusion criteria included the
following: parkinsonism due to diseases other than PD,
the presence of other serious diseases, malignant tumor(s),
or adverse events caused by drugs.
The clinical study is registered at UMIN clinical trial
registry (UMIN-CTR) UMIN000010014 (February 13,
2013). The Ethics Committee of the Juntendo UniversitySchool of Medicine approved this study in February
2013, as did the ethics committees of other centers, and
all participants provided signed informed consent forms.
Randomization and blinding
The enrolled participants have been assigned using a
stratified randomization method according to their age
and if they were receiving levodopa. The assignments
were made by C.S. The participants and those assessing
outcomes will remain blinded until all the participants
have finished the protocol.
Procedures
On a daily basis, the participants will drink 1,000 mL of
saturated H2-water containing 5 mM of dissolved H2
(using Hydrogen 7.0, supplied by Ecomo International
Co., Ltd. [Fukuoka, Japan]; patent No: PCT/JP2011/
063601) for 72 weeks. The placebo water is saturated
with N2. The water is contained in a 500-mL plastic bot-
tle, and the participants will drink 2 bottles per day. The
participants will drink the water within 3 h of opening
the cap, because H2 evaporates. The bottles of H2-water
or placebo water will be sent to the participants’ home
every week.
The schedule of the study is shown in Fig. 1. Changes
in the total UPDRS scores from baseline to the 8th, 24th,
48th, and 72nd weeks, and after the 8th week, are evalu-
ated. The primary endpoint of the efficacy of this treat-
ment in PD is the change in the total UPDRS score from
baseline to the 72nd week.
The changes in UPDRS part II, UPDRS part III, each
UPDRS score, PD Questionnaire-39 (PDQ-39), and the
H & Y stage at these same time-points, as well as the
duration until the protocol is finished because additional
levodopa is required or until the disease progresses, will
also be analyzed. Adverse events and screening labora-
tory parameters (total protein, albumin, alkaline phos-
phatase, aspartate transaminase, alanine transaminase,
serum urea nitrogen, calcium, chloride, creatinine, glu-
cose, lactate dehydrogenase, potassium, sodium, creatin-
ine kinase, uric acid, choline esterase, LDL-cholesterol,
HDL-cholesterol, and triglyceride levels) will also be
examined.
Statistical analysis
We calculated that a minimum of 95.4 participants need
to be enrolled to detect a 5-point difference in the
UPDRS scores between the 2 groups, with a standard
deviation of the mean difference of 10, and a 2-sided
alpha level of 0.05 and 80 %. Assuming a 35 % dropout,
96 participants will be required in total. A period of
72 weeks’ follow-up is a relatively long-term clinical trial
in PD; hence, we assumed a 35 % dropout rate.
Study period
Time point Enrolment Allocation
Baseline/ 
0th week

















Fig. 1 Schedule of enrolment, intervention, and assessment. Study period of enrolment, allocation, and baseline may coincide. It is approximately
1 week to 10 days from allocation to the first day to start shipping the water. *1: Unified Parkinson’s Disease Rating Scale. *2: Parkinson’s
Disease Questionnaire-39
Table 1 The baseline characteristics of the study participants
Mean Std. Deviation
Age 64.2 9.2
Disease duration 6.8 4.5
Sex (male/female) n 89 89
Wearing off (+/-) n 58 120
Dyskinesia (+/-) n 42 136
Levodopa mg 344.1 202.8
Levodopa (+/-) n 154 24
Dopamine agonist levodopa equivalent
dose (mg) [12]
166.3 121.1
Total levodopa equivalent dose (mg) [12]a 592.0 317.6
Unified Parkinson’s Disease Rating Scale
Part I 0.7 1.2
Part II 5.6 3.9
Part III 15.7 8.4
Part IV 1.7 2.2
Total 23.7 11.8
Modified Hoehn and Yahr stage 2.1 0.6
Parkinson’s disease Questionnaire-39
Mobility 10.4 9.1
Activities of daily living 5.2 5.1
Emotional well-being 6.0 4.4
Stigma 3.2 2.8
Social support 1.4 1.9
Cognitions 4.0 3.0
Communication 1.7 2.2
Body discomfort 2.5 2.6
Total 34.4 24.2
a: not including istradefylline and zonisamide
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and treatment assessment points will be compared be-
tween the groups, using a t-test or a Mann–Whitney U-
test. The statistical tests are 2-sided, and the significance
level is set at 0.05. The number of participants in the
treatment and placebo groups who drop out due to dis-
ease progression will be analyzed using Kaplan −Meier
curves and the log-rank test. Subgroup analysis (sex, and
treatment with or without levodopa) will be performed.
Enrollment and data collection
One-hundred-and-seventy-eight Japanese participants
with PD have already been enrolled in 14 hospitals and
have been randomized, between April 1, 2013 and Sep-
tember 30, 2015, at their baseline visit. The participants
will be followed-up for 80 weeks. The baseline character-
istics are shown in Table 1. Despite extensive efforts to
enroll more participants, the expected number of partic-
ipants was not met, as it is difficult for some patients to
consume 1000 mL water daily.
Discussion
Fujita et al. have indicated that the intake of H2-water,
even after MPTP administration, reduces neurotoxic
damage [5]. The findings of our previous study [7] on
PD patients are in agreement with the previous results
that were obtained in animal models.
Antioxidant supplements that are considered medicinal
products should undergo sufficient evaluation before mar-
keting, as they might be harmful at high doses [9]. H2 se-
lectively reduces •OH radicals, but not O2
−•, H2O2, or NO•
[4]. It is expected that prolonged application of H2 will have
no or little adverse effects in chronic diseases. The effects
of H2 could be mediated by modulating activities and ex-
pression of various molecules, such as Lyn, ERK, p38, JNK,
ASK1, Akt, GTP-Rac1, iNOS, Nox1, NF-κB, p65, Iκba,
STST3, NFATc1, c-Fos, and ghrelin [10]. Iuchi et al. pro-
posed a hypothetical model in which H2 is linked to the
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tor of activated T cells (NFAT) pathway via oxidized
phospholipid species [11].
Our previous trial was the first randomized double-blind
study of H2-water in patients with PD [7]. H2-water exhib-
ited no adverse effects at a dose of 1000 mL/day in PD sub-
jects receiving levodopa treatment. The results of the
previous study will be confirmed in this longer and larger-
scale study that includes patients who are not medicated
with levodopa. This study will confirm the safety and toler-
ability of H2-water and if H2-water can improve PD
symptoms.
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